https://www.selleckchem.com/pr....oducts/Azacitidine(V
In this study, we aimed to develop a prognostic model to predict HCC early recurrence (within 1-year) in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE). A total of 148 HCC patients with MVI who received PA-TACE were included in this study. The modes were verified in an internal validation cohort (n=112) and an external cohort (n=36). Univariate and multivariate Cox regression analyses were performed to identify the independent prognostic factors rel
Like
Comment
Share
